Advertisement

European Journal of Clinical Pharmacology

, Volume 5, Issue 1, pp 37–43 | Cite as

Synergistic effects of a new beta-adrenergic blocker (pindolol) and isosorbidedinitrate during exercise in patients with coronary insufficiency

  • L. Adolfsson
  • N. -H. Areskog
  • C. Furberg
  • A. Granath
  • S. Zetterquist
Originals

Summary

23 male patients with coronary insufficiency on exertion underwent standardized work tests using a bicycle ergometer. In a double blind randomized trial they received oral doses of 2 mg pindolol (LB 46), 5 mg Isosorbidedinitrate (ISO), 2 mg pindolol + 5 mg isosorbidedinitrate (LBI 25) and a placebo. LBI 25, LB 46 and ISO all produced significant increases in the work performed before symptoms and signs appeared of coronary insufficiency. The mean increase in total work was: LBI 25 69%; LB 46 49%; and ISO 33%. The corresponding figures for work performed up to the time of appearance of ST-depression were: LBI 25 115%; LB 46 87%; and ISO 54%. A moderate synergism between ISO and LB 46 was found in 17 of the 23 patients. Tiredness in the legs during work was more common in patients taking beta-blocking agents. Nine patients complained of slight headache, mostly after LBI 25 and ISO.

Key words

Beta adrenergic receptor blockade nitrates placebo coronary artery disease exercise test 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adolfsson, L., Areskog, N.-H.: Effects of propranolol in patients with coronary insufficiency (in Swedish). Läkartidningen64, Suppl. III, 83–88 (1967).Google Scholar
  2. Adolfsson, L., Areskog, N.-H., Rasmuson, T.: Effects of alprenolol and sorbidnitrate during exercise in patients with coronary insufficiency. Europ. J. clin. Pharmacol.3, 68–73 (1971).Google Scholar
  3. Aravanis, Ch., Michaelides, G.: Results of the use of a new beta-adrenergic blocker (LB 46) in angina pectoris. Acta cardiol. (Brux.)25, 501–509 (1970).Google Scholar
  4. Areskog, N.-H., Adolfsson, L.: Effects of a cardio-selective beta-adrenergic blocker (ICI 50172) at exercise in angina pectoris. Brit. med. J.1969 II, 601–603.Google Scholar
  5. Areskog, N.-H., Hallén, A.: ECG at rest and ECG response to exercise. In A. Hallén, Angina pectoris. Acta chir. scand., Suppl.323, 70–88 (1964).Google Scholar
  6. Aronow, W.S., Kaplan, M.A.: Evaluation of propranolol and isosorbide dinitrate in angina pectoris. Curr. Ther. Res.11, 80–86 (1969).Google Scholar
  7. Aronow, W.S., Kaplan, M.A.: Propranolol combined with isosorbide dinitrate versus placebo in angina pectoris. New Engl. J. Med., 280 nr.16, 847–850 (1969).Google Scholar
  8. Gillam, P.M.S., Prichard, B.N.C.: Use of propranolol in angina pectoris. Brit. med. J.1965 II, 337.Google Scholar
  9. Giudicelli, J.-F., Schmitt, H., Boissier, J.: Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB 46), a new potent beta adrenergic blocking drug. J. Pharmacol. exp. Ther.168, 116–126 (1969).Google Scholar
  10. Hamer, J., Grandjean, T., Melendez, L., Sowton, G.E.: Effect of propranolol (Inderal) in angina pectoris. Brit. med. J.1964 II, 720–723.Google Scholar
  11. Kaltenbach, M., Becker, H.J., Graef, V., Hunscha, H.: Zur Therapie der Angina pectoris mit Beta-Rezeptorenblockern. Med. Klin.65, 494–500 (1970).Google Scholar
  12. Kaltenbach, M.: Untersuchung über die Wirkung einer Kombination von Beta-Rezeptorenblockern mit Nitroglyzerinkörpern in der Therapie der Angina Pectoris. In: Aktuelle Probleme der β-Rezeptorenblockade, Intern. Symp. Kronberg/Taunus, 19.–20. X. 1968, pp. 149–159. Hrsg.: F. Bender. Stuttgart, New York: F. K. Schattauer Verlag 1970.Google Scholar
  13. Lang, E., Haas, W., Heck, J.: Zur klinischen Pharmakologie der Beta-Sympathikolyse. Eine vergleichende Prüfung von LB 46 und Propranolol. Med. Klin.65, 2206–2211 (1970).Google Scholar
  14. Levy, J.V.: Cardiovascular effects of prinodolol (LB 46), a potent beta-adrenergic receptor antagonist. J. clin. Pharmacol., July–August, 249–260 (1971).Google Scholar
  15. Rose, G.A.: The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull. Wld. Hlth. Org.27, 645–658 (1962).Google Scholar
  16. Russek, H.I.: Propranolol and isosorbide dinitrate synergism in angina pectoris. Amer. J. Cardiol.21, 44–54 (1968).Google Scholar
  17. Russek, H.I.: New dimension in angina pectoris therapy. Geriatrics, March 81–95 (1969).Google Scholar
  18. Sainani, G.S., Mukherjee, A.K.: A double-blind drug trial of a new beta adrenergic blocking agent LB 46 in the treatment of angina pectoris. In: XIth International Congress of Internal Medicine, Oct. 25–30, pp. 24–25 (1970).Google Scholar
  19. Sjöstrand, T.: (ed.) Clinical Physiology. Pathophysiological basis and practical application, pp. 515–529. Stockholm: Svenska Bokförlaget 1967.Google Scholar
  20. Srivastava, S.C., Dewar, H.A., Newell, D.J.: Double-blind trial of propranolol (Inderal) in angina of effert. Brit. med. J.1964 II, 724.Google Scholar
  21. Srivastava, B.N., Deshmankar, B.S., Vyas, G.P., Khare, R.P., Rao, V.S., Gupta, R.K.: Pilot studies on LB 46, a new beta receptor blocking agent in normal volunteers. J. Assoc. Phycns India19, 68 (1971).Google Scholar
  22. Storstein-Spilker, L.: The influence of the beta-receptor blocking agent LB 46, isosorbidedinitrate and their combination on the exercise-ecg. Cardiovascular Research, Abstracts, VI World Congress of Cardiology, p. 298, 1970.Google Scholar
  23. Westling, H.: In “Angina Pectoris. Nordic Symposium in Göteborg, Sweden 1969”. (Ed. Varnauskas, E., Werkö, L.). 175–187 (1969).Google Scholar

Copyright information

© Springer-Verlag 1972

Authors and Affiliations

  • L. Adolfsson
    • 1
  • N. -H. Areskog
    • 1
  • C. Furberg
    • 1
  • A. Granath
    • 1
  • S. Zetterquist
    • 1
  1. 1.Departments of Clinical Physiology, Linköping, Boden and DanderydSweden

Personalised recommendations